Royce & Associates’s Tandem Diabetes Care TNDM Stock Holding History

Royce & Associates’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.6M	Buy	900,590 +204,000	+29%	+$3.56M	0.11%	312
2026 Q1	$13.4M	Buy	696,590 +46,340	+7%	+$1.01M	0.13%	256
2025 Q4	$14.3M	Buy	650,250 +140,250	+28%	+$2.53M	0.14%	214
2025 Q3	$6.19M	Buy	+510,000	New	+$6.9M	0.06%	424
2021 Q3	–	Sell	-78,286	Closed	-$7.63M	–	1015
2021 Q2	$7.63M	Buy	78,286 +9,900	+14%	+$883K	0.05%	505
2021 Q1	$6.04M	Buy	68,386 +1,300	+2%	+$121K	0.04%	564
2020 Q4	$6.42M	Buy	67,086 +31,800	+90%	+$3.28M	0.05%	498
2020 Q3	$4M	Buy	35,286 +11,700	+50%	+$1.23M	0.04%	518
2020 Q2	$2.33M	Sell	23,586 -14,000	-37%	-$1.12M	0.03%	635
2020 Q1	$2.42M	Sell	37,586 -29,500	-44%	-$2.07M	0.03%	550
2019 Q4	$4M	Buy	67,086 +16,586	+33%	+$1.02M	0.04%	544
2019 Q3	$2.98M	Buy	+50,500	New	+$3.22M	0.03%	611

Other funds holding TNDM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Royce & Associates's TNDM Position: Q2 2026 in Review

Royce & Associates increased its Tandem Diabetes Care (TNDM) stake by 29% in Q2 2026, buying an estimated $3.56M and bringing the position to 900,590 shares worth $13.6M. The position accounts for 0.11% of the portfolio, ranked #312.

Royce & Associates first reported a position in TNDM in Q3 2019 and has held it in 12 quarters since. The position peaked at $14.3M in Q4 2025. 273 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.

Royce & Associates held 900,590 shares of Tandem Diabetes Care worth $13.6M as of Q2 2026.
Royce & Associates bought 204,000 Tandem Diabetes Care shares in Q2 2026, an estimated $3.56M.
Tandem Diabetes Care made up 0.11% of Royce & Associates's portfolio in Q2 2026, its #312 holding.
Royce & Associates first reported a position in Tandem Diabetes Care in Q3 2019 and has held it in 12 quarters since.
Royce & Associates's Tandem Diabetes Care position peaked at $14.3M in Q4 2025.
273 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.